# Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

> **NCT05595499** · PHASE2 · RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 88 (estimated)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Fisetin
- **DRUG:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05595499
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-27
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2025-07-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05595499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05595499, "Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05595499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*